▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

ETF Series Solutions - Range Cancer Therapeutics ETF (NASDAQ: CNCR)

$13.04

(0.2%)

$0.03

Price as of January 7, 2025, 11:24 a.m. ET

ETF Series Solutions - Range Cancer Therapeutics ETF Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
CNCR	-2.46%	-41.39%	-10.13%	-50%
S&P	+27.21%	+83.69%	+12.93%	+195%

ETF Series Solutions - Range Cancer Therapeutics ETF Company Info

Loncar Cancer Immunotherapy ETF

News & Analysis

Featured Article

3 Index Funds to Buy in August

Our contributors take a look at three index funds in promising areas such as emerging markets, cancer immunotherapy, and banks.

Andrés Cardenal, Jason Hall, and George Budwell | Aug 1, 2016

Featured Article

3 High-Growth ETFs to Supercharge Your Portfolio

Exposing your portfolio to high-growth industries while staying diversified is a way to boost your portfolio with less risk.

Cory Renauer, Matt Frankel, and Brian Feroldi | Jun 1, 2016

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services